Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001193125-26-149642
Filing Date
2026-04-09
Accepted
2026-04-09 16:15:06
Documents
1
Period of Report
2026-03-13

Document Format Files

Seq Description Document Type Size
1 3 ownership.html 3  
1 3 ownership.xml 3 2379
  Complete submission text file 0001193125-26-149642.txt   3900
Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 212-994-8250
MiNK Therapeutics, Inc. (Issuer) CIK: 0001840229 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 3 FORBES ROAD LEXINGTON MA 02421
Business Address
Orilall Melissa (Reporting) CIK: 0002125307 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-40908 | Film No.: 26851750